CN104684904B - 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚 - Google Patents

通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚 Download PDF

Info

Publication number
CN104684904B
CN104684904B CN201380051147.7A CN201380051147A CN104684904B CN 104684904 B CN104684904 B CN 104684904B CN 201380051147 A CN201380051147 A CN 201380051147A CN 104684904 B CN104684904 B CN 104684904B
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380051147.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104684904A (zh
Inventor
W·B·艾姆
R·M·伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN104684904A publication Critical patent/CN104684904A/zh
Application granted granted Critical
Publication of CN104684904B publication Critical patent/CN104684904B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380051147.7A 2012-08-27 2013-08-23 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚 Expired - Fee Related CN104684904B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693437P 2012-08-27 2012-08-27
US61/693,437 2012-08-27
PCT/US2013/056418 WO2014035827A1 (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (2)

Publication Number Publication Date
CN104684904A CN104684904A (zh) 2015-06-03
CN104684904B true CN104684904B (zh) 2017-10-13

Family

ID=49117974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380051147.7A Expired - Fee Related CN104684904B (zh) 2012-08-27 2013-08-23 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚

Country Status (11)

Country Link
US (2) US9024042B2 (enExample)
EP (1) EP2888239B1 (enExample)
JP (1) JP6270848B2 (enExample)
KR (2) KR102304111B1 (enExample)
CN (1) CN104684904B (enExample)
AU (1) AU2013309124B2 (enExample)
CA (1) CA2882743C (enExample)
DK (1) DK2888239T3 (enExample)
ES (1) ES2711425T3 (enExample)
TR (1) TR201900863T4 (enExample)
WO (1) WO2014035827A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684904B (zh) 2012-08-27 2017-10-13 阿勒根公司 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
CA2939569A1 (en) * 2014-02-20 2015-11-19 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
WO2015179815A1 (en) * 2014-05-22 2015-11-26 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
CN111978310A (zh) 2014-10-02 2020-11-24 阿勒根公司 γ-内酰胺的酯前药及其用途
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008718A3 (en) * 2006-07-11 2008-03-13 Allergan Inc Cyclopentane derivatives as antiglaucoma agents
US20090270396A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds
US20100210689A1 (en) * 2007-07-13 2010-08-19 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
CN102007098A (zh) * 2008-03-18 2011-04-06 阿勒根公司 治疗性的取代的环戊烷

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE10322843A1 (de) 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
EP2291346A2 (en) * 2008-05-15 2011-03-09 Allergan, Inc. Therapeutic substituted cyclopentanes
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CN104684904B (zh) 2012-08-27 2017-10-13 阿勒根公司 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008718A3 (en) * 2006-07-11 2008-03-13 Allergan Inc Cyclopentane derivatives as antiglaucoma agents
US20100210689A1 (en) * 2007-07-13 2010-08-19 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
CN102007098A (zh) * 2008-03-18 2011-04-06 阿勒根公司 治疗性的取代的环戊烷
US20090270396A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
JP6270848B2 (ja) 2018-01-31
CA2882743C (en) 2021-11-30
DK2888239T3 (en) 2019-03-04
TR201900863T4 (tr) 2019-02-21
KR102304111B1 (ko) 2021-09-23
AU2013309124A1 (en) 2015-03-12
EP2888239A1 (en) 2015-07-01
CN104684904A (zh) 2015-06-03
US9427401B2 (en) 2016-08-30
CA2882743A1 (en) 2014-03-06
US20150322036A1 (en) 2015-11-12
JP2015528463A (ja) 2015-09-28
WO2014035827A1 (en) 2014-03-06
AU2013309124B2 (en) 2018-03-01
ES2711425T3 (es) 2019-05-03
US9024042B2 (en) 2015-05-05
HK1211031A1 (en) 2016-05-13
EP2888239B1 (en) 2018-11-28
US20140057975A1 (en) 2014-02-27
KR20200110820A (ko) 2020-09-25
KR20150046269A (ko) 2015-04-29

Similar Documents

Publication Publication Date Title
CN104684904B (zh) 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
AU2015259752B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CN107074832B (zh) γ-内酰胺的酯前药及其用途
HK1211031B (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
HK40041854A (en) Ester prodrugs of gamma-lactams and their use
HK1229812A1 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211031

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1211031

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171013

CF01 Termination of patent right due to non-payment of annual fee